Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Lung Neoplasms 28Ovarian Neoplasms 27Fallopian Tube Neoplasms 24Carcinoma, Non-Small-Cell Lung 21Colorectal Neoplasms 17Glioblastoma 11Pancreatic Neoplasms 10Melanoma 10Carcinoma, Renal Cell 10Carcinoma, Hepatocellular 10Breast Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Lymphoma, Large B-Cell, Diffuse 8Urinary Bladder Neoplasms 7Neoplasm Metastasis 7Colonic Neoplasms 7Brenner Tumor 7Uterine Cervical Neoplasms 6Rectal Neoplasms 6Prostatic Neoplasms 6Mycosis Fungoides 6Leukemia, Lymphocytic, Chronic, B-Cell 6Brain Neoplasms 6Triple Negative Breast Neoplasms 5Multiple Myeloma 5Lymphoma, T-Cell, Cutaneous 5Sezary Syndrome 4Sarcoma 4Neoplasms 4Nasopharyngeal Carcinoma 4

Interventions

Octreotide 4Leucovorin 3Trastuzumab 2Temozolomide 2Oxaliplatin 2Fluorouracil 2Capecitabine 2Bevacizumab 2veliparib 1vatalanib 1tipifarnib 1pentetreotide 1motesanib diphosphate 1epothilone B 1batifiban 1Thalidomide 1Sorafenib 1Salts 1Melphalan 1Irinotecan 1Interleukin-12 Subunit p35 1Interleukin-12 1Immunoglobulin G 1Gefitinib 1Floxuridine 1Fentanyl 1Everolimus 1Disulfides 1Biological Therapy 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Vipoma × Disulfides × Clear all
NCT01229943 2022-08-04

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
150 enrolled 12 charts

Vipoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡